ARTICLE | Clinical News
Alagebrium: Phase IIa discontinued
February 6, 2006 8:00 AM UTC
ALT withdrew its IND for the Phase IIa EMERALD trial of alagebrium for ED and discontinued development in the indication. FDA had placed the trial on clinical hold following a review of preclinical to...